Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/18—Growth factors; Growth regulators
  • A61K38/1825—Fibroblast growth factor [FGF]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/18—Growth factors; Growth regulators
  • A61K38/1808—Epidermal growth factor [EGF] urogastrone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

• This invention relates to methods for protecting neural cells against injury and death, as a result of trauma, neurodegenerative disease processes, toxic insult, malfunction, or aging by providing factors to the central nervous system of a subject.
• Neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease,
• Huntington's disease, multiple and amyotrophic lateral sclerosis, stroke, schizophrenia, epilepsy and diabetic peripheral neuropathy are diseases or disorders which affect millions of people. It is the loss of normal neuronal function which produces the behavioral and physical deficits which are characteristic of each of the different neurological disorders.
• the aging process and physical trauma to the central nervous system both result in the loss of neural cells accompanied by the associated behavioral and physical deficits.
• neurological disorders have become an important concern due to the expanding elderly population which is at greatest risk for these disorders.
• U.S. Patent No. 5,519,035, issued on May 21, 1996 provides a method of treating a patient at risk for stroke with protein kinase C inhibitor in order to protect neuronal cells from death as a result of cerebral ischemia.
• Sufficient protein kinase C inhibitor is administered on a daily basis to ensure that, should an ischemic insult occur, the levels of the agent would be high enough to counteract the neurotoxic effects of nitric oxide produced during the ischemic event.
• Parkinson's disease characterized by the loss of dopamine neurons in the nigrostriatal pathway, is a relatively common neurological disorder.
• the dopaminergic neurotoxin, l-methyI-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) produces parkinsonian symptoms when administered to humans and is frequently used to induce parkinsonionism in animal models of Parkinson's disease.
• Tomac et al. (1995) (Nature 373 pp 335-339) reported that glial cell line derived neurotrophic factor (GDNF) has a protective effect on dopaminergic neurons when the factor is injected into mouse brain 24 hours before administration of MPTP.
• GDNF glial cell line derived neurotrophic factor
• U.S. Patent 5,438,121 issued on August 1, 1995, relating to brain-derived neurotrophic factor (BDNF), disclosed that BDNF may be added to cell cultures 24 hours prior to exposure to the neurotoxins MPP and 6-OHDA to reduce the amount of cellular damage caused by the neurotoxins.
• U.S. Patent 5,554,601 issued on September 10, 1996 disclosed a method of protecting cells in the central nervous system from cell death through the stimulation of the production of neurotrophic growth factors in ovarectomized animals. The method relies on the chronic administration of an estrogen compound having a unique structure which allows it to cross the blood brain barrier in order to stimulate the production of neurotrophic growth factor proteins such as nerve growth factor (NGF) and BDNF.
• NGF nerve growth factor
• the effect of the estrogen compounds was believed to be due to their protective actions against hypoglycemia and excitatory amino acids, and their stimulatory effects on neurotrophic growth factor production in ovarectomized animals. It was noted that the protective effect was not due to a mitogenic effect of the steroid on neural tissue.
• Methods are provided for protecting mammalian neural tissue from trauma or insult or from the mamfestations of neurological disease or disorders or the aging process.
• the method comprises administering to a mammal an effective amount of one or more growth factors to induce multipotent neural stem cell proliferation which results in a protective effect on the neural tissue.
• the growth factor treatment can be completed while the neural tissue is still healthy to provided a prolonged protective effect which lasts weeks and even months after cessation of the treatment.
• Growth factors such as EGF, amphiregulin, fibroblast growth factor, transforming growth factor alpha, and the like, and combinations thereof can be exogenously administered to the mammal, for example, to one or more CNS ventricles of the mammal.
• the growth factors can be administered by genetically modifying cells of the mammalian neural tissue to produce the growth factors.
• the growth factors are administered at a time prior to the onset of the trauma or the manifestations of the disease or aging process, in amounts sufficient to cause the neural cell population to be protected from progressive cell damage leading to the death of the cells or their malfunction.
• the invention is also directed to the use of a growth factor, or a combination of growth factors in the manufacture of a medicament for the preventative treatment of neurological or neurodegenerative diseases or disorders, neurological trauma, and/or the aging of neural tissue.
• Fig. 1A-1F depict photomicrographs of Nissl stained coronal sections (10 ⁇ m, bregma -3.3 mm) of control (no pretreatment, non-ischemic; 1A, IB) or one week post-ischemic (IC to 2F) rats that received either vehicle (IC and ID) or EGF (IE and IF) i.e. v. infusion t months prior to an ischemic insult.
• CA1 neurons are present in the non-ischemic controls (1A and IB) and in the EGF-pretreated ischemic animals (IE and IF), but are absent in the vehicle-pretreated ischemic animals (IC and ID), demonstrating that EGF pretreatment can protect against ischemia-induced cell death in the CA1 region of the hippocampus.
• the present invention provides methods for the protection of neural tissue from the effects of aging, trauma, toxic insult, neurological diseases or disorders.
• Growth factors are administered to the neural tissue, at a time prior to the onset of trauma or the manifestations of neurological disease or aging, to induce multipotent neural stem cells and neural stem cell progeny to proliferate and generate progeny cells that are capable of differentiating into neurons, astrocytes, and oligodendrocytes.
• Astrocytes in particular have been shown to provide a supportive and protective role in the brain. These cells buffer the environment around neurons and secrete factors which enhance the survival and function of the neurons. Normally, astrocyte turnover in the CNS is limited and large scale replacement of dysfunctional astrocytes has not been reported.
• a “multipotent neural stem cell” is an undifferentiated neural cell which is capable of extensive self renewal, i.e., is capable of replacing itself during cell division over an extended period of time, and is capable of generating the major cell types of the tissues in which it is located (i.e. neurons and glia - astrocytes and oligodendrocytes).
• the non-stem cell progeny of a neural stem cell are termed progenitor cells. Methods of proliferating neural stem cells in vitro and in vivo have been previously described (see e.g. WO 93/01275, WO 94/10292, and U.S. Ser. No. 08/486,648).
• neural progenitor cell refers to an undifferentiated cell derived from a neural stem cell, and is not itself a stem cell.
• a distinguishing feature of a progenitor cell is that, unlike a stem cell, it has limited proliferative ability and thus does not exhibit self-maintenance. It is committed to a particular path of differentiation and will, under appropriate conditions, eventually differentiate into either glia (astrocytes or oligodendrocytes) or neurons, and is thus not multipotent.
• precursor cells refers to the progeny of neural stem cells, and thus includes both progenitor cells and daughter neural stem cells.
• ventricle refers to any cavity or passageway within the CNS through which cerebral spinal fluid flows and includes any collapsed portions of the ventricular system. Thus, the term not only encompasses the lateral, third, and fourth ventricles, but also encompasses the central canal, cerebral aqueduct, and other CNS cavities and collapsed CNS cavities.
• growth factor refers to a protein, peptide or other molecule having a growth, proliferative, differentiative, or tropic effect on neural stem cells and/or neural stem cell progeny.
• Growth factors which may be used for inducing proliferation include any factor that allows neural stem cells and precursor cells to proliferate, including any molecule which binds to a receptor on the surface of the neural stem cell to exert a tropic, or growth-inducing effect on the cell, including any protein, amino acid, vitamin, carbohydrate, or other molecule or atom.
• Preferred proliferation-inducing growth factors include EGF, amphiregulin, acidic fibroblast growth factor (aFGF or FGF-1), basic f ⁇ broblast growth factor
• bFGF or FGF-2 trarisforming growth factor alpha (TGF ⁇ ), proliferation-inducing ligands which bind to the EGF and FGF receptors, and combinations thereof.
• a preferred combination of proliferation-inducing growth factors is EGF or TGF ⁇ with FGF-1 or FGF-2.
• neural stem cell progeny that have been induced to proliferate in vivo by administration of growth factors undergo differentiation into cell types that are beneficial to the treated area.
• a likely mechanism is that the neural stem cell progeny respond to extrinsic signals that influence them to differentiate into needed cell types.
• Differentiated progeny of neural stem cells include neurons, astrocytes (type I or type 2) and oligodendrocytes.
• the differentiative pathway of the neural stem cell progeny can be influenced by the addition of exogenous growth factors that increase the numbers of a particular cell type that are generated. Differentiation-influencing growth factors that can be exogenously added are disclosed in WO 94/10292 and U.S. Ser. No. 08/486,648.
• FGF-1 FGF-2
• FGF-2 ciliary neurotrophic factor
• NGF NGF
• BDNF neurotrophin 3
• neurotrophin 4 interleukins
• LIF leukemia inhibitory factor
• cyclic adenosine monophosphate forskolin, high levels of potassium, amphiregulin, TGF- ⁇ , TGF- ⁇ , insulin-like growth factors, dexamethasone (glucocorticoid hormone), isobutyl 3-methylxanthine, somatostatin, growth hormone, retinoic acid, and PDGF, or ligands which bind to the receptors for these growth factors.
• the effects of various growth factors on differentiation can be tested in vitro on cultures of multipotent neural stem cell progeny by using dual-label immunocytochemistry various neuronal- and glial-specific antibodies, the effect of the exogenous growth factors on the differentiation of the cells can be determined.
• Type I astrocytes which are differentiated glial cells, can be identified by their immunoreactivity for GFAP but not A2B5.
• Type II astrocytes which are differentiated glial cells that display a stellate process-bearing mo ⁇ hology, can be identified using immunocytochemistry by their phenotype GFAP(+), A2B5(+) phenotype.
• Growth factors can be administered singly or in combination to a patient. They can also be administered in a temporal sequence (e.g. exposure to a first growth factor influences the expression of a second growth factor receptor, Neuron 4: 189-201 (1990).
• the growth factors may be prepared in a pharmaceutically-acceptable excipient.
• Administration of the growth factors can be done by any method, including injection cannula or injection to the CNS, peripheral injection, timed- release apparati which can administer substances at the desired site, oral administration, and the like.
• Growth factors can be administered using methods in which the factors may either pass through or by-pass the blood-brain barrier. Methods for allowing factors to pass through the blood-brain barrier include minimizing the size of the factor, or providing hydrophobic factors which may pass through more easily.
• DMSO dimethyl sulfoxide
• i.v. intravenously
• i.p. intraperitoneally
• growth factor growth factor into the CNS.
• Doses of DMSO in mice would be from 2-30% DMSO in a volume of approximately 0.25 ml, administered i.v., preferably 10-15%.
• An intraperitoneal administration of DMSO and growth factor would require from 10-30% DMSO. It would be possible to use Boradeption (Science 217: 166 (1982)) Another possibility would be to bind the growth factor to transferrin to transfer it across the blood brain barrier.
• the fact that the majority of neural stem cells are located in the tissues lining ventricles of mature brains offers several advantages for the modification and manipulation of these cells in vivo. Treatment can be tailored accordingly so that stem cells surrounding ventricles near the desired region would be manipulated or modified in vivo using the methods described herein.
• the ventricular system is found in nearly all brain regions and thus allows easier access to the desired areas. If one wants to modify the stem cells in vivo by exposing them to a composition comprising a growth factor or a viral vector, it is relatively easy to implant a device that administers the composition to the ventricle and thus, to the neural stem cells.
• a cannula attached to an osmotic pump may be used to deliver the composition.
• the composition may be injected directly into the ventricles.
• the neural stem cell progeny can migrate into regions that may be subjected to possible damage as a result of injury, disease, or aging.
• the close proximity of the ventricles to many brain regions would allow for the diffusion of a secreted neurological agent by the stem cells or their progeny to the appropriate region.
• the precursor cells can be genetically modified in vivo by transfection of the cells with growth factor or hormone-expressing vectors, so that the neural cells express various biological agents useful in the prevention of neurological disorders, trauma and the effects of aging.
• Methods for genetically modifying multipotent neural stem cells and their progeny are disclosed in published international application no. WO 94/16718.
• the cells may be modified to express other types of neurological agents such as neurotransmitters.
• the genetic modification is performed either by infection of the cells lining ventricular regions with recombinant retroviruses or transfection using methods known in the art including CaPO 4 transfection, DEAE-dextran transfection, polybrene transfection, by protoplast fusion, electroporation, lipofection, and the like [see Maniatis et al., Molecular Cloning: A Laboratory Manual (1989), 2nd Ed., Cold Spring Harbor, N.Y.]. Any method of genetic modification, now known or later developed can be used. With direct DNA transfection, cells could be modified by particle bombardment, receptor mediated delivery, and cationic liposomes.
• chimeric gene constructs When chimeric gene constructs are used, they generally will contain viral, for example retroviral long terminal repeat (LTR), simian virus 40 (SV40), cytomegalo virus (CMV); or mammalian cell-specific promoters such as those for TH, DBH, phenylefhanolamine N-methyltransferase, ChAT, GFAP, NSE, the NF proteins (NF-L, NF-M, NF-H, and the like) that direct the expression of the structural genes encoding the desired protein.
• LTR retroviral long terminal repeat
• SV40 simian virus 40
• CMV cytomegalo virus
• mammalian cell-specific promoters such as those for TH, DBH, phenylefhanolamine N-methyltransferase, ChAT, GFAP, NSE, the NF proteins (NF-L, NF-M, NF-H, and the like) that direct the expression of the structural genes
• Any expression vector known in the art can be used to express the growth factor, as long as it has a promoter which is active in the cell, and appropriate termination and polyadenylation signals.
• These expression vectors include recombinant vaccinia virus vectors including pSCll, or vectors derived various viruses such as from Simian Virus 40 (SV40, i.e. pSV2-dhfr, ⁇ SV2neo, pko-neo, pSV2gpt, pSVT7 and pBABY), from Rous Sarcoma Virus (RSV, i.e. pRSVneo), from mouse mammary tumor virus (MMTV, i.e.
• Simian Virus 40 i.e. pSV2-dhfr, ⁇ SV2neo, pko-neo, pSV2gpt, pSVT7 and pBABY
• RSV Rous Sarcoma Virus
• MMTV
• pMSG adenovirus(pMT2)
• HSV herpes simplex virus
• BPV bovine papillomavirus
• EBV Epstein-Barr Virus
• p205 and pHEBo Epstein-Barr Virus
• a retroviral construct is to be used to genetically modify normally quiescent stem cells, then it is preferable to induce the proliferation of these cells using the methods described herein.
• an osmotic infusion pump could be used to deliver growth factors to the central canal several days prior to infection with the retrovirus. This assures that there will be actively dividing neural stem cells which are susceptible to infection with the retrovirus.
• the deficits in movement, cognition, memory and other behavioral symptoms which normally occur in subjects with neurological disorders caused by disease, trauma or aging or a combination of these factors are reduced as a consequence of preventative administration of a growth factor or growth factors capable of stimulating the proliferation of multipotent neural stem cells and/or their progeny.
• the growth factor pretreatment method achieves a prolonged protective effect, thereby eliminating the need for the exogenously administered growth factor to be present at the time of the trauma, disease, or disorder.
• the term "protective effect" means that the growth factor treatment results in a significantly greater number of normally functioning neural cells than would have otherwise been without the growth factor pre-treatment.
• the growth factors may be administered on an ongoing basis or at regular intervals prior to the manifestations of aging or neurological disorders or disease and from one week to several weeks prior to an anticipated neurological trauma or insult, such as what might occur during brain surgery.
• the term "manifestation” refers to the outward sign of a neurological disease or disorder or the aging process.
• clinical memory loss is an outward sign of Alzheimer's Disease, and can be an outward sign of the aging process.
• certain biological processes that ultimately lead to cell death, injury or dysfunction such as the over- or under-expression of certain gene products, may be early events that begin prior to the onset of outward signs of the aging process, neurological diseases and/or disorders.
• Diagnosis of these biological processes or other precursor events of the aging process, neurological disease and/or disorder followed by a suitable growth factor treatment may lead to the prevention or reduction of the manifestations of the aging process and neurological diseases and disorders.
• genetic screening can be used to diagnose patients who are predisposed to certain neurological disorders, such as Huntington's Disease, prior to the onset of manifestations of the disorder. Patients found to be at risk for a neurological disease or disorder can be treated with growth factors to prevent or reduce the progression of the disease.
• Growth factors are administered (or neural cells are genetically modified to express growth factors) prior to the onset of trauma or the manifestations of aging or disease processes at concentrations that are sufficient to result in neural stem cell proliferation.
• the protective effects that are provided by the growth factor treatment are long-term and usually continue for at least one week after treatment has ceased.
• the protective benefits are often sustained at least two weeks after cessation of treatment, and in many cases, a protective effect is sustained for one, and up to two months, or more.
• growth factors or other neurological agents would be delivered to the ventricles of the forebrain to affect in vivo proliferation of the stem cells.
• growth factors and other neurological agents can be easily administered to the lumbar cistern for circulation throughout the CNS.
• Animal models for various neurological diseases, disorders and injury are used to assess the protective effect of growth factor administration to establish suitable dosages and methods of treatment.
• Behavioral testing is performed to compare the abilities of growth factor treated animals with non-treated control animals. Such behavioral tests include learning and memory tests such as the Morris water maze and radial arm maze.
• the data obtained from accepted mammalian animal models, particularly rodent, canine, and primate models are extrapolated to determine suitable protocols for growth factor treatment of humans.
• administration of from about 100 to about 1000 ng growth factor per kilogram of body weight per hour over a period of from about 1 to 10 days is sufficient to induce multipotent neural stem cell proliferation.
• Example 2 demonstrates that epidermal growth factor (EGF), administered icv at a physiologically effective dose, exerts a cytoprotective effect on hippocampal neurons in vivo, preventing the normal neuronal degenerative response following an ischemic insult. While not wishing to be bound by theory, this response appears to be due to the result of the mitogenic effect of the growth factors, resulting in the production of new neural cells, possibly as a result of the induction of proliferation, migration and/or differentiation of quiescent neural stem and progenitor cells and leading to the production of new glial and/or neuronal cells which secrete substances or alter the environment, providing a long term protective effect on the neurons even after the exogenously administered growth factors are no longer present.
• EGF epidermal growth factor
• a patient scheduled to undergo brain surgery may be pretreated with growth factors to prevent neurological trauma.
• growth factors Prior to surgery, growth factors would be administered to brain regions that may be effected during the surgical procedure. Growth factors are administered at least one week prior to the expected CNS trauma. Preferably, the growth factors would be administered at least two, and more preferably, at least four or more weeks prior to the expected trauma to provide time for the proliferation and differentiation of a beneficial number of new neural stem cell progeny.
• the growth factor pretreatment could be completed several weeks in advance of surgery because the protective effect of growth factor pretreatment is observed for prolonged periods after cessation of the treatment.
• Certain types of professional athletes such as boxers, are also at high risk for neurological trauma, and could be treated with growth factors to achieve a neuroprotective effect. Additionally, patients who are at high risk for stroke can be treated with growth factors to reduce the amount of neurological damage should a stroke occur.
• Example 3 demonstrates that in very old animals, the ability to generate an active constitutively proliferating progenitor cell (CPC) population is impaired.
• CPC progenitor cell
• Neural precursor populations are shown to decline with age, perhaps as a result of a slowing stem cell cycle time. This in turn may lead to degenerative changes in brain morphology, increased susceptibility to ischemic and toxic insults, and increased frequency of cognitive disorders that are often seen in aged animals.
• administration of growth factors such as EGF and FGF to the healthy CNS results in the presence of more healthy, young cells in the aging brain.
• healthy CNS tissue it is meant that the stem cell cycle time and the neural tissue in general are normal for mammals of the same species and age group.
• the treated mammal has at least a 5% increase, and more preferably, a 10% increase, in the number of CPCs relative to the average CPC count for age-matched mammals of the same species.
• the increase in CPC count is sustained for extended time periods, preferably for at least one to two months, and more preferably, for at least four months after cessation of growth factor treatment.
• Example 1 In Vivo Proliferation of Neural Stem Cells of Lateral Ventricle
• a replication incompetent retrovirus containing the ⁇ -galactosidase gene [as described in Walsh and Cepko, Science 241:1342, (1988)] was injected into the forebrain lateral ventricles of CD1 adult male mice (25-30 g from Charles River).
• the injected retrovirus was harvested from the BAG cell line (ATCC CRL-9560) according to the method of Walsh and Cepko (supra). Mice were anesthetized using 65 mg/kg, i.p. sodium pentobarbital.
• Unilateral stereotactic injections of 0.2-1.0 ⁇ l of retrovirus were injected into the lateral ventricle using a 1 ⁇ l Hamilton syringe.
• the coordinates for injection were AP +4.2 mm anterior to lambda, L +. 0.7 mm, and DV -2.3 mm below dura, with the mouth bar at -2mm below the interaural line.
• an infusion cannulae attached to a 0.5 ⁇ l/hour ALZET osmotic mini-pumps filled with 3.3 - 330 ⁇ g/ml of EGF were surgically implanted into the lateral ventricles at the identical stereotactic coordinates as stated above.
• the infusion cannula kits were obtained from ALZA.
• the infusion cannulae were cut to 2.7 mm below the pedestal.
• the pumps were secured to the mouse skull by use of acrylic cement and a skull screw contralateral and caudal to the injection site.
• the osmotic mini-pump was situated subcutaneously under and behind the armpit of the left front paw and connected to the infusion cannula by the means of polyethylene tubing.
• infusion of EGF resulted in an expansion of the population of ⁇ -gal labeled cells from an average of 20 cells per brain up to an average of 150 cells per brain and the migration of these cells away from the lining of the lateral ventricles.
• Infusion of FGF-2 at 33 ⁇ g/ml resulted in an increase in the number of ⁇ -gal labeled cells, but this increase was not accompanied by any additional migration.
• Infusion of EGF and FGF together resulted in an even greater expansion of the population of ⁇ -gal labeled cells from 20 cells per brain to an average of 350 cells per brain.
• the synergistic increase in ⁇ -galactosidase cell number when EGF and FGF are infused together further reflects the direct association between the relatively quiescent stem cell and the constitutively proliferating progenitor cell.
• This experiment can be modified to infuse growth factors in other CNS ventricles to achieve a similar expansion of cell numbers in other CNS regions.
• Example 2 Growth Factor Infusion Prior to Neurological Insult Epidermal Growth Factor (EGF) (Chiron Corp.) was prepared in 1 mg/ml rat albumin (Calbiochem, Cat. No. 126722) in sterile physiological saline. The EGF preparation was infused into the rostral lateral ventricle (Bregma +0.7 mm) of adult male Wistar rats weighing 250- 350 g via a 30 gauge cannula connected to an osmotic minipump (Alza, Model 2001) at a rate of 1 ⁇ l/hr for 9 days. The EGF was prepared at a concentration so as to provide each animal with 416 ng EGF per kilogram of body weight every hour.
• EGF Neurological Insult Epidermal Growth Factor
• the model used was a combination of rodent models used routinely for transient global ischemia which combines bilateral common carotid artery occlusion with hemorrhagic hypotension (Smith et al. Act. Neurol. Scand 6j9_:385-401 (1984); Mudrick and Baimbridge, Exp'l Brain Res. £6:233-247 (1991)).
• This model produced lesions of the neurons in the CAl region (100% of animals) and in the CA2 and CA3 regions (60% of animals) of the hippocampus bilaterally.
• the animals were anesthetized with sodium pentobarbital (60 mg/kg i.p.) and treated with atropine (0.2 mg/kg i.p.) to reduce respiratory secretions.
• a rectal temperature probe connected to a temperature regulated heat pad, was used to maintain the animal body temperature at 35°C.
• the common carotid arteries and the femoral artery were isolated using blunt dissection and a 3-0 silk was looped around each vessel for later access. The femoral artery was then cannulated and heparin (150 units) was administered to prevent clotting.
• the baseline mean arterial pressure was taken ( - 120/80 mmHg) via a transducer and recorded on a chart recorder.
• the animal was hemorrhaged until mean arterial pressure fell to 30-40 mmHg (removal of approximately 7-10 ml of blood).
• the common carotid arteries were quickly occluded with atraumatic arterial clamps for 20 minutes.
• Mean arterial pressure was maintained at 30-40 mmHg throughout the duration of the ischemia by either further hemorrhage or reinfusion of blood. Blood flow was restored by removal of the arterial clamps, and reinfusion of shed blood.
• Protamine sulfate 1.5 mg/animal was administered via the femoral cannula to deactivate heparin to prevent post-surgical bleeding.
• Mean arterial pressure should return to pre-ischemic levels or slightly higher.
• the animal was given 5 ml of lactated Ringers s.c. and allowed to recover under a warm lamp. The animal was single-housed and monitored closely for the next 48 hours.
• Tissue processed for morphology was defatted in Histoclear (Diamed, Cat. No. HS- 200), rehydrated through a descending series of alcohols, rinsed in distilled water and stained with Thionin (0.5%). Tissue was then dehydrated through a series of alcohols, cleared with Histoclear, and coverslipped with DPX (Aldrich, Cat. No. 31761-1). Thionin stains the Nissl substance within the cytoplasm of nerve cells (Cajal, 1995). The absence of cells with the characteristic pyramidal cell morphology within the cell layer is indicative of a loss of hippocampal pyramidal neurons due to ischemia- induced cell death.
• a one week post ischemia survival time was chosen due to the unique characteristic of delayed neuronal death observed in CAl pyramidal cells in response to transient global ischemia (Shigeno et al. . Neurosci. 11:2914-2919 (1991); Ordy et al. Exp'l Neurol. 119:128-139 (1993)) whereby select CAl pyramidal cells appear unaffected by ischemia for up to 3 days post surgery. In addition, maximal glial reaction has occurred and excitotoxic conditions have subsided by this time point.
• EGF pretreatment icv infusion of EGF for a 9 day period
• EGF-treated animals revealed that the cells of the CAl, CA2 and CA3 displayed excellent morphology throughout the extent of the hippocampus ( Figure 1).
• Example 3 Growth Factor Administration Prior to Onset of Advanced Aging Assessment of precursor cells in rodents of various ages
• the adult subventricular zone consists of at least two populations of dividing cells that can be distinguished by differences in their cell cycle times: a slowly cycling stem cell population and a rapidly cycling, constitutively proliferating progenitor cell (CPC) population.
• CPC constitutively proliferating progenitor cell
• mice of various ages were injected with BrdU (approximately 67 mg/kg) for 4 weeks (3-5 times/day) and left undisturbed for a further 8 weeks.
• This paradigm resulted in labeling of the slowly cycling stem cells of the subventricular zone. Animals were perfused with 4% paraformaldehyde and the brains are removed and cryoprotected. Frozen sections were cut at 30 ⁇ m. BrdU was detected immunocytochemically (rat anti-BrdU, Sera labs, followed by donkey anti-rat CY3 or FITC, Jackson Immunoresearch). Labeled cells throughout the brain were quantified and changes in cell numbers or distribution with age were analyzed. In addition, the distribution of BrdU-immunoreactive, post-mitotic stem cell progeny in the brain was quantified and compared among ages.
• PCNA proliferating cell nuclear antigen
• EGF-treated animals are allowed to age and are given a variety of memory and other behavioral tests and compared with animals of the same age that have not received EGF treatments. Improved performance of EGF-treated animals compared to non-treated animals demonstrates that pretreatment with growth factors can protect against or reduce age-related declines in cognitive function.
• Parkinson's Disease Model Animals receive EGF infusion treatments as described in Example 2 for 6 days (mice) or 9 days (rats). After various time points (1 wk, 2 wk, 1 mo., 2 mos., 4 mos. and 8 mos.) after EGF treatment, animals are lesioned so as to model Parkinson's Disease. In rat models, lesions are made by knife-cuts of the dopaminergic fibers projecting from the midbrain to the striatum or by one injection of 8 ⁇ g of 6-hydroxydopamine directly into the striatum, nucleus accumbens or the substantia nigra.
• mice lesions are made by administration of two injections at 16 hours interval, of 50 mg MPTP/Kg subcutaneously in volume of 0.5 ml of 0.9% saline solution.
• a subset of animals are allowed to survive one to eight days after lesioning and are then sacrificed.
• the numbers of surviving dopaminergic cells are assayed by tyrosine hydroxylase (TH) immunocytochemistry and are compared with control animals that are lesioned prior to sacrifice but which do not receive growth factor treatment.
• TH tyrosine hydroxylase
• mice Female Wistar rats (180-200 g) are used for this model. The animals receive EGF infusion treatments as described in Example 2 for 9 days. After various time points (1 wk, 2 wk, 1 mo., 2 mos., 4 mos. and 8 mos.) after EGF treatment, animals are lesioned so as to model Alzheimer's Disease. A retractable wire knife (Scouten Knife) is used to partially lesion the fimbria-fornix pathway. Animals are killed at various time points after the lesion (from 1 day to 8 weeks), and the numbers of surviving cells are assayed by Nissel staining in the septum. Controls, lesioned and treated animals are compared. A subset of animals is allowed to survive for prolonged periods for behavioral studies and compared with control animals.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Behavior & Ethology (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Organic Chemistry (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Magnetic Heads (AREA)
• Chemical Vapour Deposition (AREA)
• Carbon And Carbon Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=21854421

Family Applications (1)

Country Status (6)

Families Citing this family (8)

Family Cites Families (3)

• 1997
  • 1997-11-14 CA CA002266659A patent/CA2266659A1/en not_active Abandoned
  • 1997-11-14 JP JP52302998A patent/JP2001504123A/ja active Pending
  • 1997-11-14 EP EP97913033A patent/EP0941109A1/de not_active Withdrawn
  • 1997-11-14 AU AU50433/98A patent/AU5043398A/en not_active Abandoned
  • 1997-11-14 WO PCT/CA1997/000859 patent/WO1998022127A1/en not_active Application Discontinuation
• 1999
  • 1999-05-14 NO NO992364A patent/NO992364L/no not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events